Abstract
Introduction

38
Canine brucellosis, caused by Brucella canis, is a worldwide bacterial disease that affects 39 dogs and has been shown to constitute a risk for humans (1) . Traditionally the infection has been 40 associated with kennels, but nowadays it has been spread through various dog populations,
41
including shelter and stray dogs (2). It causes mainly reproductive disorders, such as abortions 42 and infertility. Furthermore, signs of canine brucellosis might not become apparent for many 43 years on infected animals (3), making difficult to implement measurements to avoid the spread of 44 the disease to non-infected animals.
45
Methods to control the disease are based solely in diagnostic tests, such as Rapid Slide
46
Agglutination Test with 2-mercaptoethanol (2ME-RSAT), agar gel immunodiffusion test (AGID) 47 or ELISA (4, 5); and control actions to avoid the contagion of healthy animals (6 Mice were bled by submandibular puncture every 2 weeks before and after the challenge. 
Statistical analysis of data
200
The CFU data were normalized by log transformation and evaluated by ANOVA followed 
301
When selecting immunization strategies for a trial with pets, the site of injection and the 302 adjuvant to be used should be considered. Vaccines containing recombinant antigens may be less 303 reactogenic but also less immunogenic, thus necessitating the inclusion of an adjuvant (28).
304
However, the adjuvant should be chosen considering the benefits and risks for the target species.
305
In this study, we selected three commercial adjuvants approved for use in dogs, along with IFA,
306
since it has been used in previous works of Omp31 (20, 21, 34 
